CNSP Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (18 Apr 2024 @ 16:00):

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors...

Stats
Today's Volume	131 366
Average Volume	438 251
Market Cap	2.17M
EPS	$0 ( 2024-04-01 )
Next earnings date	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0200
ATR14	$0.00300 (1.47%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-08	Mahery Amy	Buy	17 500	Restricted Stock Units
2024-04-08	Mahery Amy	Buy	17 500	Option to purchase common stock
2024-04-08	Keyes Jeffry R.	Buy	17 500	Restricted Stock Units
2024-04-08	Keyes Jeffry R.	Buy	17 500	Option to purchase common stock
2024-04-08	Gumulka Jerzy	Buy	17 500	Restricted Stock Units

INSIDER POWER
95.19
Last 96 transactions
Buy: 4 147 286 \| Sell: 1 591 936

Volume Correlation

Long: -0.10 (neutral)

Short: 0.80 (moderate)

Signal:(52.577) Neutral

CNS Pharmaceuticals Inc Correlation

10 Most Positive Correlations
TDAC	0.958
GAINL	0.947
THMO	0.941
HUSN	0.939
UK	0.935
RMRM	0.924
BIOL	0.924
KBSF	0.922
GRNV	0.921
APOP	0.918

10 Most Negative Correlations
BOCH	-0.96
SHSP	-0.937
HEES	-0.92
LMST	-0.914
LOPE	-0.914
KBWP	-0.908
PI	-0.908
LMRK	-0.905
HOLX	-0.905
INNV	-0.901

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

CNS Pharmaceuticals Inc Correlation - Currency/Commodity

0.38
( neutral )

0.44
( neutral )

0.00
( neutral )

-0.40
( neutral )

CNS Pharmaceuticals Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-4 134.00 (0.00 %)
EPS:	$-5.00

Q4	2023
Revenue:	$0
Gross Profit:	$-953.00 (0.00 %)
EPS:	$-0.950

Q3	2023
Revenue:	$0
Gross Profit:	$-899.00 (0.00 %)
EPS:	$-1.080

Q2	2023
Revenue:	$0
Gross Profit:	$-1 003.00 (0.00 %)
EPS:	$-1.040

Financial Reports:

No articles found.

CNS Pharmaceuticals Inc

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.